Detailed information for compound 2008889
Basic information
Technical information
- Name: Unnamed compound
- MW: 321.294 | Formula: C17H14F3NO2
-
H donors: 2
H acceptors: 2
LogP: 3.02
Rotable bonds: 4
Rule of 5 violations (Lipinski): 1 - SMILES: CCNC(=O)c1ccc2c(c1)C(O)(c1c2cccc1)C(F)(F)F
- InChi: 1S/C17H14F3NO2/c1-2-21-15(22)10-7-8-12-11-5-3-4-6-13(11)16(23,14(12)9-10)17(18,19)20/h3-9,23H,2H2,1H3,(H,21,22)
- InChiKey: TWLQGAMSVRSJMX-UHFFFAOYSA-N
Network
Hover on a compound node to display the structore
Synonyms
No synonyms found for this compound
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Homo sapiens | pyruvate dehydrogenase kinase, isozyme 2 | Starlite/ChEMBL | No references |
Predicted pathogen targets for this compound
By orthology
By sequence similarity to non orthologous known druggable targets
| Species | Potential target | Known druggable target | Length | Alignment span | Identity |
|---|---|---|---|---|---|
| Trypanosoma brucei | pyruvate dehydrogenase (lipoamide) kinase, putative | pyruvate dehydrogenase kinase, isozyme 2 | 343 aa | 321 aa | 22.7 % |
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Schistosoma mansoni | pyruvate dehydrogenase | 0.0144 | 1 | 1 |
| Echinococcus multilocularis | Pyruvate dehydrogenase (lipoamide) kinase | 0.0144 | 1 | 0.5 |
| Toxoplasma gondii | ATPase/histidine kinase/DNA gyrase B/HSP90 domain-containing protein | 0.0058 | 0 | 0.5 |
| Echinococcus granulosus | Pyruvate dehydrogenase lipoamide kinase | 0.0144 | 1 | 0.5 |
| Echinococcus multilocularis | Pyruvate dehydrogenase (lipoamide) kinase | 0.0144 | 1 | 0.5 |
| Trypanosoma cruzi | developmentally regulated phosphoprotein, putative | 0.0144 | 1 | 0.5 |
| Trypanosoma brucei | developmentally regulated phosphoprotein | 0.0144 | 1 | 0.5 |
| Leishmania major | developmentally regulated phosphoprotein-like protein | 0.0144 | 1 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0144 | 1 | 0.5 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| IC50 (binding) | = 6371 nM | BindingDB_Patents: Inhibition Assay. The inhibitory action of PDHK activity was indirectly evaluated by performing a kinase reaction in the presence of a test compound and measuring the residual PDH activity. For expression of hPDHK2 activity, Escherichia coli strain BL21(DE3) cells (Novagen) were transformed with the pET17b vector containing modified hPDHK2 cDNA. Escherichia coli were grown to an optical density 0.6 (600 nmol/L) at 30C. Protein expression was induced by the addition of 500 umol/L isopropyl-beta-thiogalactopyranoside. Escherichia coli were cultured at 30 C. for 5 hr and harvested by centrifugation. Resuspension of the Escherichia coli paste was disrupted by a microfluidizer. FLAG-Tagged protein was separated using FLAG affinity gel (Sigma). The gel was washed with 20 mmol/L N-(2-hydroxyethyl)piperazine-N'-2-ethanesulfonic acid-sodium hydroxide (HEPES-NaOH), 500 mmol/L sodium chloride, 1% ethylene glycol, and 0.1% Pluronic F-68 (pH 8.0), and the binding protein was eluted with 20 mmol/L HEPES. | ChEMBL. | No reference |
Phenotypes
Whole-cell/tissue/organism interactions
We have no records of whole-cell/tissue assays done with this compound
What does this mean?
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL3676662
Bibliographic References
No literature references available for this target.
If you have references for this compound, please enter them in a user comment (below) or Contact us.